Stock A335810 PRECISION BIOSENSOR, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Precision Biosensor, Inc.

Equities

A335810

KR7335810008

Medical Equipment, Supplies & Distribution

End-of-day quote Korea S.E.
Other stock markets
 23:00:00 23/05/2024 BST 		5-day change 1st Jan Change
4,250 KRW +1.19% Intraday chart for Precision Biosensor, Inc. -0.70% -10.90%
03-25 Qlife Signs Letter of Intent with Precision Biosensor CI
02-08 Precision Biosensor, Inc. announced that it has received KRW 3 billion in funding from Shinhan Investment & Securities Co., Ltd., Korea Investment & Securities Co., Ltd. CI

Valuation

Fiscal Period: December 2020 2021 2022 2023
Capitalization 1 385,102 126,163 68,644 55,401
Enterprise Value (EV) 1 362,117 113,132 76,549 69,184
P/E ratio -62.3 x -30.2 x -10 x -12.3 x
Yield - - - -
Capitalization / Revenue 44.3 x 7.94 x 3.36 x 2.72 x
EV / Revenue 41.7 x 7.12 x 3.74 x 3.39 x
EV / EBITDA -382 x -36.6 x -34.5 x -41.5 x
EV / FCF -94.6 x -7.83 x -6.76 x -6.47 x
FCF Yield -1.06% -12.8% -14.8% -15.5%
Price to Book 10.3 x 3.29 x 2.06 x 1.73 x
Nbr of stocks (in thousands) 11,244 11,366 11,576 11,615
Reference price 2 34,250 11,100 5,930 4,770
Announcement Date 16/03/21 15/03/22 17/03/23 19/03/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023
Net sales 1 8,685 15,887 20,458 20,391
EBITDA 1 -948 -3,091 -2,218 -1,665
EBIT 1 -1,719 -4,269 -4,500 -4,811
Operating Margin -19.79% -26.87% -22% -23.59%
Earnings before Tax (EBT) 1 -4,953 -4,281 -7,005 -5,382
Net income 1 -4,953 -4,152 -6,806 -4,490
Net margin -57.03% -26.14% -33.27% -22.02%
EPS 2 -550.0 -368.0 -590.5 -387.0
Free Cash Flow 1 -3,828 -14,441 -11,321 -10,697
FCF margin -44.07% -90.9% -55.34% -52.46%
FCF Conversion (EBITDA) - - - -
FCF Conversion (Net income) - - - -
Dividend per Share - - - -
Announcement Date 16/03/21 15/03/22 17/03/23 19/03/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023
Net Debt 1 - - 7,904 13,783
Net Cash position 1 22,985 13,032 - -
Leverage (Debt/EBITDA) - - -3.564 x -8.276 x
Free Cash Flow 1 -3,828 -14,441 -11,321 -10,697
ROE (net income / shareholders' equity) -20.4% -11% -19% -13.7%
ROA (Net income/ Total Assets) -3.38% -5.45% -4.9% -4.95%
Assets 1 146,481 76,247 138,815 90,721
Book Value Per Share 2 3,310 3,374 2,879 2,758
Cash Flow per Share 2 1,948 488.0 652.0 209.0
Capex 1 2,110 9,151 11,142 7,053
Capex / Sales 24.3% 57.6% 54.46% 34.59%
Announcement Date 16/03/21 15/03/22 17/03/23 19/03/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Diagnostic & Testing Substances

1st Jan change Capi.
PRECISION BIOSENSOR, INC. Stock Precision Biosensor, Inc.
-10.90% 36.16M
BIOMÉRIEUX Stock bioMérieux
-4.92% 12.27B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD. Stock Shenzhen New Industries Biomedical Engineering Co., Ltd.
-5.82% 7.99B
DIASORIN S.P.A. Stock DiaSorin S.p.A.
+5.43% 5.69B
LANTHEUS HOLDINGS, INC. Stock Lantheus Holdings, Inc.
+26.16% 5.42B
AUTOBIO DIAGNOSTICS CO., LTD. Stock Autobio Diagnostics Co., Ltd.
-9.58% 4.13B
10X GENOMICS, INC. Stock 10x Genomics, Inc.
-59.63% 2.7B
ANDON HEALTH CO., LTD. Stock Andon Health Co., Ltd.
+8.44% 2.6B
VITROLIFE AB Stock Vitrolife AB
-3.70% 2.38B
MYRIAD GENETICS, INC. Stock Myriad Genetics, Inc.
+21.00% 2.1B
Diagnostic & Testing Substances
  1. Stock Market
  2. Equities
  3. A335810 Stock
  4. Financials Precision Biosensor, Inc.